Skip to main content
. 2024 Nov 15;16(11):e73727. doi: 10.7759/cureus.73727

Table 2. Safety data of biosimilar Pegaspargase (Asviia).

Adverse Events Number (n=45) (%)
Sepsis/febrile neutropenia 8 17.8
Allergy 6 13.3
Vomiting 6 13.3
Hyperglycemia 5 11.1
Transaminitis event 2 4.44
Pancreatitis 2 4.44
Bilirubin >3 mg/dL 2 4.44
Seizure 0 0
Encephalopathy syndrome 0 0
Albumin <2 g/dL 0 0
Life threat/intervention needed 0 0